Therefore, further long-term, randomized, double-blinded, multi-centered clinical trials of SGLT2 inhibitors on hepatic fibrosis and steatosis are needed to help patients and physicians make the best treatment decisions. This evidence concerns the gene SLC5A2 and steatosis.